Eli Lilly-Morphic deal receives US antitrust clearance
Eli Lilly and biotech company Morphic Holding have received clearance for their $3.2 billion deal from the US antitrust authorities. The initial waiting period under the Hart-Scott-Rodino Act expired on July...To view the full article, register now.
Already a subscriber? Click here to view full article